M J Overman1, L Adam1, K Raghav1, J Wang2, B Kee1, D Fogelman1, C Eng1, E Vilar1, R Shroff1, A Dasari1, R Wolff1, J Morris3, E Karunasena4, T R Pisanic2, N Azad4, S Kopetz1. 1. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 2. Institute for NanoBioTechnology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA. 3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Gastrointestinal Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, USA.
Abstract
Background: Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC. Patients and methods: The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was initially administered at a dose of 260 mg/m2 every 3 weeks but was reduced to 220 mg/m2 owing to toxicity. Results: A total of 21 patients with CIMP-high CRC and 13 with SBA were enrolled from November 2012 to October 2014. The efficacy-assessable population (patients who received at least three doses of the treatment) comprised 15 CIMP-high CRC patients and 10 SBA patients. Common grade 3 or 4 toxicities were fatigue (12%), neutropenia (9%), febrile neutropenia (9%), dehydration (6%), and thrombocytopenia (6%). No responses were seen in the CIMP-high CRC cohort and two partial responses were seen in the SBA cohort. Median progression-free survival was significantly greater in the SBA cohort than in the CIMP-high CRC cohort (3.2 months compared with 2.1 months, P = 0.03). Neither APC mutation status nor CHFR methylation status correlated with efficacy in the CIMP-high CRC cohort. In vivo testing of paclitaxel in an SBA patient-derived xenograft validated the activity of taxanes in this disease type. Conclusion: Although preclinical studies suggested taxane sensitivity was associated with chromosomal stability and wild-type APC, we found that nab-paclitaxel was inactive in CIMP-high metastatic CRC. Nab-paclitaxel may represent a novel therapeutic option for SBA.
Background: Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC. Patients and methods: The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was initially administered at a dose of 260 mg/m2 every 3 weeks but was reduced to 220 mg/m2 owing to toxicity. Results: A total of 21 patients with CIMP-high CRC and 13 with SBA were enrolled from November 2012 to October 2014. The efficacy-assessable population (patients who received at least three doses of the treatment) comprised 15 CIMP-high CRC patients and 10 SBApatients. Common grade 3 or 4 toxicities were fatigue (12%), neutropenia (9%), febrile neutropenia (9%), dehydration (6%), and thrombocytopenia (6%). No responses were seen in the CIMP-high CRC cohort and two partial responses were seen in the SBA cohort. Median progression-free survival was significantly greater in the SBA cohort than in the CIMP-high CRC cohort (3.2 months compared with 2.1 months, P = 0.03). Neither APC mutation status nor CHFR methylation status correlated with efficacy in the CIMP-high CRC cohort. In vivo testing of paclitaxel in an SBApatient-derived xenograft validated the activity of taxanes in this disease type. Conclusion: Although preclinical studies suggested taxane sensitivity was associated with chromosomal stability and wild-type APC, we found that nab-paclitaxel was inactive in CIMP-high metastatic CRC. Nab-paclitaxel may represent a novel therapeutic option for SBA.
Authors: Aziz Zaanan; Mélanie Gauthier; David Malka; Christophe Locher; Jean-Marc Gornet; Anne Thirot-Bidault; David Tougeron; Julien Taïeb; Franck Bonnetain; Thomas Aparicio Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: C C J M Simons; L A E Hughes; K M Smits; C A Khalid-de Bakker; A P de Bruïne; B Carvalho; G A Meijer; L J Schouten; P A van den Brandt; M P Weijenberg; M van Engeland Journal: Ann Oncol Date: 2013-03-26 Impact factor: 32.976
Authors: Yu-Wei Cheng; Hanna Pincas; Manny D Bacolod; Gunter Schemmann; Sarah F Giardina; Jianmin Huang; Sandra Barral; Kamran Idrees; Sajid A Khan; Zhaoshi Zeng; Shoshana Rosenberg; Daniel A Notterman; Jurg Ott; Philip Paty; Francis Barany Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: Lorraine Pelosof; Sashidhar R Yerram; Nita Ahuja; Andrew Delmas; Ludmila Danilova; James G Herman; Nilofer S Azad Journal: Int J Cancer Date: 2013-08-24 Impact factor: 7.396
Authors: Michael J Overman; Scott Kopetz; Sijin Wen; Paulo M Hoff; David Fogelman; Jeffrey Morris; James L Abbruzzese; Jaffer A Ajani; Robert A Wolff Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Alexa B Schrock; Craig E Devoe; Robert McWilliams; James Sun; Thomas Aparicio; Philip J Stephens; Jeffrey S Ross; Richard Wilson; Vincent A Miller; Siraj M Ali; Michael J Overman Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777
Authors: Charles Swanton; Michela Marani; Olivier Pardo; Patricia H Warne; Gavin Kelly; Erik Sahai; Frédéric Elustondo; Jenny Chang; Jillian Temple; Ahmed A Ahmed; James D Brenton; Julian Downward; Barbara Nicke Journal: Cancer Cell Date: 2007-06 Impact factor: 31.743
Authors: S Y Moorcraft; I Chau; C Peckitt; D Cunningham; S Rao; K L Yim; A Walther; C G C A Jackson; G Stamp; J Webb; G Smith; A Gillbanks; C Swanton Journal: Invest New Drugs Date: 2013-06-26 Impact factor: 3.850
Authors: Yongjun Cha; Sun Young Kim; Hyun Yang Yeo; Ji Yeon Baek; Moon Ki Choi; Kyung Hae Jung; Seung Myung Dong; Hee Jin Chang Journal: Neoplasia Date: 2018-12-15 Impact factor: 5.715
Authors: Marina Baretti; Enusha Karunasena; Marianna Zahurak; Rosalind Walker; Yang Zhao; Thomas R Pisanic; Tza-Huei Wang; Tim F Greten; Austin G Duffy; Elske Gootjes; Gerrit Meijer; Henk M W Verheul; Nita Ahuja; James G Herman; Nilofer S Azad Journal: Clin Transl Sci Date: 2021-04-03 Impact factor: 4.689